...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Translational Oncology >Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects
【24h】

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects

机译：癌症免疫疗法的癌症-睾丸抗原肽疫苗：进展与展望

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cancer vaccines, including peptide-based vaccines, have been considered a key tool of effective and protective cancer immunotherapy because of their capacity to provide long-term clinical benefit for tumors. Among a large number of explorations of peptide antigen-based vaccines, cancer-testis antigens (CTAs), which are activated in cancers but silenced in normal tissues (except testis tissue), are considered as ideal targets. Currently, personalized treatment for cancer has become a trend due to its superior clinical efficacy. Thus, we envisage rational selection of CTA peptides to design “personalized” CTA peptide vaccines. This review summarizes the advances in CTA peptide vaccine research and discusses the feasibility of establishing “personalized” CTA peptide vaccines.
机译：癌症疫苗，包括基于肽的疫苗，因其能够为肿瘤提供长期临床利益而被认为是有效和保护性癌症免疫疗法的关键工具。在许多基于肽抗原的疫苗的探索中，癌症中激活但在正常组织（睾丸组织除外）中沉默的癌-睾丸抗原（CTA）被认为是理想的靶标。目前，由于其优异的临床功效，针对癌症的个性化治疗已成为一种趋势。因此，我们设想合理选择CTA肽以设计“个性化” CTA肽疫苗。这篇综述总结了CTA肽疫苗研究的进展，并讨论了建立“个性化” CTA肽疫苗的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号